Rob Rodrigues

Partner

Bio

Rob Rodrigues is a seasoned litigator specializing in high-stakes business and intellectual property disputes in Brazil. Renowned for his strategic acumen, Rob delivers unmatched expertise to FORTUNE 500 companies and dynamic startups alike. He expertly navigates complex legal landscapes, ensuring robust patent portfolio management for top-tier life sciences and telecommunications firms. His deep market insight positions him as a first-choice advisor for both acquisition and enforcement actions.

Rob's excellence has been recognized by a number of leading publications. In 2024, Lexology listed him as a Legal Influencer in Dispute Resolution. Chambers describes Rob as a "superb litigator", "a very competent professional", and "outstanding in providing business-oriented advice." Who's Who Legal praises "his top-tier practice advising clients on life sciences-related patent litigation." The Legal 500 reports that clients describe Rob as someone "who stands out for his strong background in both the IP area, both in terms of litigation and in relation to more technical topics." Client testimonials in IAM Strategy 300 laud him for his "deep understanding of IP issues and keen strategic insight, which he leverages to add value and monetise portfolios."

Throughout his career, Rob has spearheaded multiple preliminary injunction proceedings and trials for global companies in Brazil. He also facilitates monumental IP asset transactions, with a keen eye on managing risks.

A Stanford Law School LL.M. alumnus, Rob served as a lead editor of the Stanford Technology Law Review. He has contributed extensively to global technology law journals and currently holds an editorial role at the Kluwer IP Blog.

Education

- LL.M. in Law, Science and Technology, from Stanford Law School.

- Residential Scholarship at Hoover IP Institute on the Economics and Politics of Innovation.

- J.D. from Universidade Federal do Rio de Janeiro (UFRJ).

Languages

Portuguese, English, Spanish

Publications

Legal & Regulatory Updates
Legal & Regulatory Updates

Desafios Regulatórios para o Anonimato na Internet no Contexto Nacional

A regulação do anonimato digital no Brasil enfrenta desafios, buscando equilibrar liberdade de expressão com responsabilização por conteúdos ilícitos.
2025
4
min read
Legal & Regulatory Updates
Legal & Regulatory Updates

Brazil Regulates Clinical Research Act: A Complete Review of Decree #12,651/2025 - Part. 1

Decree 12,651/2025 operationalizes Brazil’s Clinical Research Act by establishing SINEP/INAEP, enforcing binding ethics and regulatory timelines, enabling single-CEP opinions for multicenter trials, and opening integrated INAEP–Anvisa procedures—setting the stage for faster, more predictable studies.
2025
7
min read
Legal & Regulatory Updates
Legal & Regulatory Updates

Updates on the Brazilian Clinical Research Landscape: What’s at Stake in ADI 7875

ADI 7875 challenges key provisions of Brazil’s Clinical Research Act on constitutional grounds—post-trial access, consent in emergencies, institutional liability—putting legal certainty at risk even as long-awaited regulations near publication.
2025
8
min read
Life Sciences & Health
Life Sciences & Health

Brazilian Clinics and the False Equivalence of Compounded GLP-1 Drugs: ANVISA should follow FDA

U.S. FDA enforcement against compounded GLP-1 products highlights false equivalence claims on safety and efficacy, and Brazil faces a similar clinic-driven market—calling for ANVISA to tighten oversight, curb trademark misuse, and enforce compounding and dispensing rules.
2025
7
min read
Legal & Regulatory Updates
Legal & Regulatory Updates

Toward Leadership: How Brazil can Unlock Clinical Trials with Regulation, Transparency and Technology

Brazil can unlock leadership in clinical trials by pairing its new legal framework with clear implementing rules, better transparency tools, and technology integration—especially AI-enabled Real-World Evidence—while balancing IP protection and patient access.
2025
8
min read